In today’s briefing:
- Caregen (214370 KS): Business Recovery Backed by Strong Global Demand; New Products Brighten Outlook
- 10 in 10 with Quantum Healthcare – Transformed for Future-Resiliency
- Medlive Technology (2192.HK) 22H1- The Growth Logic/Business Model Is More Scrutinized by the Market
Caregen (214370 KS): Business Recovery Backed by Strong Global Demand; New Products Brighten Outlook
- Caregen Co Ltd (214370 KS) is a niche biotech company, with focus on biomimetic peptide-based cosmeceuticals and medical devices targeting anti-aging industry. The company has a large addressable market opportunity.
- Despite the negative impact from the re-spread of COVID-19, Caregen reported 4% y/y growth in total revenue in H1 2022, with operating profit margin expanding 260bps.
- Caregen’s COVID-19 nasal spray is in phase 1 trial. FDA has registered Caregen’s health functional food to control blood sugar as a new dietary ingredient (NDI).
10 in 10 with Quantum Healthcare – Transformed for Future-Resiliency
10 in 10 with Quantum Healthcare – Transformed for Future-Resiliency
Medlive Technology (2192.HK) 22H1- The Growth Logic/Business Model Is More Scrutinized by the Market
- The improvement of Medlive’s profitability in 22H1 seems more related to the large decreased income tax expense rather than any obvious improvement of main business or any other logic.
- The single main business structure and insufficient core competitiveness add uncertainty to the Company’s long-term prospects, which makes it difficult to significantly improve the valuation.
- Medlive is under double pressure of “squeezing bubble” in healthcare industry and “the fading of traffic dividend” in Internet industry.Its growth logic/business model will be more scrutinized by the market.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars